# Sun Yat-sen University: Phase 3 study in Non-Clear Cell Renal Cell Carcinoma (nccRCC) (108 participants)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | Sun Yat-sen University |
| Sponsor type | Academic and hospital |
| Study | A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell Carcinoma |
| NCT ID | NCT07904156 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Non-Clear Cell Renal Cell Carcinoma (nccRCC) |
| Intervention types | drug |
| Target enrollment | 108 |
| Posted | 2026-10-29 |
| Planned start | 2026-10-21 |
| Event | Newly registered study |
| Event date | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- Phase 3: multi-site, larger budget.
- 108 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07904156). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.